Staying up late every night can easily lead to many diseases because the body doesn't get proper rest and recovery, making it harder to fight off viruses. So, how is lymphoma treated? How is it diagnosed?
Lymphoma is a malignant tumor originating from the lymphatic system, and it is divided into two main categories: Hodgkin's lymphoma and non-Hodgkin's lymphoma. Its occurrence is related to the malignant transformation of immune cells produced by the proliferation and differentiation of lymphocytes. Its etiology is not yet fully understood, but it may be related to infection with some viruses, such as Epstein-Barr virus (EBV), hepatitis viruses, and Helicobacter pylori virus.
The treatment strategy for lymphoma is a comprehensive approach with chemotherapy as the mainstay. With the development of monoclonal antibody targeted therapy, lymphoma treatment has seen a revolutionary breakthrough. Because rituximab (MabThera) has a different mechanism of action than traditional chemotherapy drugs, the two are often used in combination. The most commonly used regimen in clinical practice is the R-CHOP regimen, which includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Globally, a new lymphoma patient is diagnosed every 9 minutes on average. The incidence rate of lymphoma in my country is 0.02‰. Approximately 25,000 new cases are diagnosed annually, with nearly 20,000 deaths, demonstrating the rapidly growing threat of lymphoma. In Asia, the incidence of non-Hodgkin's lymphoma is significantly higher than that of Hodgkin's disease, approximately 9:1. Due to its higher malignancy and worse prognosis, lymphoma generally refers to non-Hodgkin's lymphoma. In my country, it ranks 9th among malignant tumors in men and 10th in women. Non-Hodgkin's lymphoma can occur at any age, with a peak incidence between 45 and 60 years of age.
In terms of diagnosis, the widespread application of immunology, molecular and cytogenetics has not only provided a unified standard for the diagnosis of malignant lymphoma, but also enabled more detailed and accurate differentiation of various subtypes of lymphoma. According to the WHO pathological classification principles, non-Hodgkin's lymphoma is subdivided into approximately 30 subtypes, some of which progress slowly while others are aggressive, and the treatment methods for different subtypes vary.